MALT1
Mucosa-associated-lymphoid-tissue (MALT1; EC 3.4.22.xx) cleavage activity is linked to the pathogenesis of activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL), a chemoresistant form of DLBCL. The caspase-like domain of MALT1 cleaves substrates following arginine residues, unlike conventional caspase that cleave after aspartate residues. MALT1 cleaves and disables A20 (TNFAIP3) and CYLD, both negative regulators of NF-κB, thereby potentiating NF-κB signaling[1].
[1] R.M. Young et al. A New “Brew” of MALT1 Inhibitors. Cancer Cell, 2012, 22(6), 706-707.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 2054 | MALT1 inhibitor MI-2 | Highly potent and selective MALT1 inhibitor | €125.00 | |
| 2193 | Thioridazine hydrochloride | DA and α1 adrenoceptor antagonist; MALT1 inhibitor | €50.00 | |